Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors

Oncotelic Therapeutics, Inc.

Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.
Each note convertible into 250,000 shares of Oncotelic at $0.10 or 25,000 EdgePoint shares at $1.00.
Each unit includes 250,000 warrants to purchase Oncotelic stock at $0.12 or EdgePoint warrants at $1.25.
Prior 2023 PPM notes settled; existing warrants extended to two years from final closing.
Registration Rights Agreement executed for shares and warrants issued in the financing.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Oncotelic Therapeutics, Inc. issued 44 units of unit to accredited investors.

Security: unit
Shares: 44 units
Purchaser: accredited investors

Exact text from the filing

On December 31, 2025, Oncotelic Therapeutics, Inc. (the " Company ") completed entering into subscription agreements with certain accredited investors (" Subscription Agreement "), whereby the Company issued a total of 44 units (" Units ") to 22 accredited investors.

View on SEC.gov

Browse all equity issuances →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.